Cargando…

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial

BACKGROUND: Enhanced de-novo collagen type VI (COL VI) formation has been associated with kidney and cardiovascular fibrosis. We hypothesized that endotrophin (ETP), a product specifically generated during collagen type VI formation, may be prognostic for heart failure (HF), cardiovascular death (CV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasmussen, Daniel Guldager Kring, Hansen, Michael K., Blair, Joseph, Jatkoe, Timothy A., Neal, Bruce, Karsdal, Morten A., Genovese, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706889/ https://www.ncbi.nlm.nih.gov/pubmed/36443792 http://dx.doi.org/10.1186/s12933-022-01666-7

Ejemplares similares

Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort
por: Møller, Alexandra Louise, et al.
Publicado: (2023)

Urinary endotrophin predicts disease progression in patients with chronic kidney disease
por: Rasmussen, Daniel Guldager Kring, et al.
Publicado: (2017)

Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes
por: Møller, Alexandra Louise, et al.
Publicado: (2023)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Endotrophin Levels Are Associated with Allograft Outcomes in Kidney Transplant Recipients
por: Sparding, Nadja, et al.
Publicado: (2023)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis
por: Sparding, Nadja, et al.
Publicado: (2021)

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
por: Neal, Bruce, et al.
Publicado: (2017)

Development of a Novel Enzyme-Linked Immunosorbent Assay Targeting a Neo-Epitope Generated by Cathepsin-Mediated Turnover of Type III Collagen and Its Application in Chronic Obstructive Pulmonary Disease
por: Rasmussen, Daniel Guldager Kring, et al.
Publicado: (2017)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
por: Wang, Katherine M., et al.
Publicado: (2021)

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2019)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Endotrophin, a fibroblast matrikine, may be a driver of fibroblast activation in fibro-inflammatory diseases
por: Reese-Petersen, Alexander L., et al.
Publicado: (2023)

Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients
por: Genovese, Federica, et al.
Publicado: (2020)

Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease
por: Fenton, Anthony, et al.
Publicado: (2017)

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
por: Zhou, Zien, et al.
Publicado: (2019)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018)

Pretransplant endotrophin predicts delayed graft function after kidney transplantation
por: Tepel, Martin, et al.
Publicado: (2022)

Urinary collagen degradation products as early markers of progressive renal fibrosis
por: Hijmans, Ryanne S., et al.
Publicado: (2017)

Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
por: Zhou, Zien, et al.
Publicado: (2019)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Noninvasive Assessment of Fibrosis Following Ischemia/Reperfusion Injury in Rodents Utilizing Na Magnetic Resonance Imaging
por: Nielsen, Per Mose, et al.
Publicado: (2020)

Collagen turnover profiles in chronic kidney disease
por: Rasmussen, Daniel Guldager Kring, et al.
Publicado: (2019)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease
por: Holm Nielsen, Signe, et al.
Publicado: (2018)

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
por: Ohkuma, Toshiaki, et al.
Publicado: (2020)

Plasma endotrophin, reflecting tissue fibrosis, is associated with graft failure and mortality in KTRs: results from two prospective cohort studies
por: Kremer, Daan, et al.
Publicado: (2022)

The novel collagen matrikine, endotrophin, is associated with mortality and cardiovascular events in patients with atherosclerosis
por: Holm Nielsen, S., et al.
Publicado: (2021)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Endotrophin is associated with chronic multimorbidity and all-cause mortality in a cohort of elderly women
por: Staunstrup, Line Mærsk, et al.
Publicado: (2021)

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020)

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
por: Carbone, Salvatore, et al.
Publicado: (2019)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort
por: Rønnow, Sarah R., et al.
Publicado: (2020)

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
por: Neal, Bruce, et al.
Publicado: (2017)

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
por: Borisov, Angel N, et al.
Publicado: (2023)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

The Mechanism for Adipose Endotrophin Production
por: Lee, Yun Sok
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jbtheol5ko1b03htbtlq1arpan